You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    SBC: ONL Therapeutics, Inc.            Topic: NEI

    PROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

    SBC: MASSACHUSETTS GENERAL HOSPITAL            Topic: NIA

    Abstract Overmillion Americans are currently affected by Alzheimerandapos s diseaseADwith an economic burden estimated at andgt$billion year inthat is projected increase at least four fold over next several decadesIn spite of the dearth of pharmacological options to modify the course of the disease at presentthe field has developed accurate biomarkers that demonstrate that the pathology of AD is p ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a novel Balloon Occlusion Sheath for Stroke (BOSS)

    SBC: Marblehead Medical LLC            Topic: 106

    PROJECT SUMMARY ABSTRACTThis research program s broadlong term objective is to improve health outcomes for patients suffering fromacute ischemic strokeAISresulting from large vessel occlusionsWe will achieve this purpose by developingimproved access tools for stroke intervention procedureswhich specifically target tool innovations that providesupport for embolectomy devices and arrest flow during ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: Bertec Corporation            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A practical platform for in-home remote monitoring of cognitive-frailty

    SBC: BioSensics LLC            Topic: NIA

    AbstractCognitive frailtythe combined presence of physical frailty and cognitive impairmentis a strong and independent predictor of cognitive declineThe International Association of Gerontology and Geriatrics and the International Academy on Nutrition and Aging have recommended the use of cognitive frailty assessment to track the progression of mild cognitive impairmentMCItowards dementiaAlzheimer ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: Velum Incorporated            Topic: NIA

    There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: NIA

    PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.

    SBC: ASPIREBIO CORP            Topic: 101

    PROJECT SUMMARY Opioid drugs are powerful analgesicsbut their side effect profile strongly limits their useIndeedtheir addictive properties have led to an epidemic of abuse in the US that accounts forof the global utilization of prescription opioid analgesics in the USwith a market of over $billion per yearPrevious studies have shown that the endocannabinoid neurotransmitteranandamidecontrols noci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Additive Manufacturing Sensor Fusion Technologies for Process Monitoring and Control.

    SBC: ARCTOS Technology Solutions, LLC            Topic: DLA18A001

    Universal Technology Corporation (UTC) has teamed with the University of Dayton Research Institute (UDRI), Stratonics, and Macy Consulting to demonstrate not only the transitionability into commercial systems, but also to develop the data analytics and monitoring and control requirements to extract the full value fromseveral sensors, including the Stratonics ThermaViz, acoustic and profilometry se ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
US Flag An Official Website of the United States Government